Roth Capital Initiates Coverage on Alnylam Pharmaceuticals (ALNY) with a Buy
ALNY Hot Sheet
Rating Summary:7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Roth Capital initiates coverage on Alnylam Pharmaceuticals (Nasdaq: ALNY) with a Buy. Price target $26.
To see more analyst ratings on ALNY Click Here.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi).
To see more analyst ratings on ALNY Click Here.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interference (RNAi).
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
